If you are launching a direct-to-consumer telehealth brand, one of the first and most consequential decisions you will make is how to structure the medical side of your business. You are building a brand and a technology company. In most states, you are not (and may not be allowed to be) the entity that practices medicine. So the real question becomes: who actually employs the clinicians, owns the patient relationship, and writes the prescriptions?
Founders generally face two paths:
- White-labeling through an existing medical network
- Building a PC/MSO structure (a professional corporation paired with a management services organization)
There is also a third approach that many fast-growing companies land on: a hybrid model that combines both strategies in a way that preserves speed now and ownership later. Read on, as we’re breaking down the difference, the pros and cons of each, the contract traps to avoid, and a simple framework to help you choose the right path.
Why this decision matters more than founders expect
In most states, the corporate practice of medicine (CPOM) doctrine limits how non-physicians and ordinary corporations can own or control medical practice operations. Add fee-splitting and anti-kickback concerns, state-by-state licensure rules, and category-specific scrutiny from regulators, and your structure stops being a formality.
It becomes the foundation of whether your model is:
- Legal
- Scalable
- Sellable
This decision also answers the questions investors and acquirers ask early. Your answers depend heavily on the structure you choose.:
- Who owns the patient relationship?
- Who owns the clinical and patient data in practice?
- Who controls clinical protocols and the brand experience?
- What are the unit economics per visit?
Option 1: White-labeling through a medical network
A white-label medical network is a turnkey clinical backend. The network supplies licensed providers (often across all 50 states), clinical protocols, e-prescribing and pharmacy fulfillment, and a HIPAA-ready platform, while your brand remains front-facing to the patient. In short: you plug into their system, point it at your funnel, and you can be seeing patients far faster than if you built everything yourself.
Pros of white-labeling
- Speed to market: You can launch in days or weeks instead of months.
- Lower upfront cost: No multi-state entity buildout or credentialing infrastructure.
- Much of the compliance burden is handled: The network carries licensure and much of the CPOM and telehealth-rule burden.
- Instant national footprint: Networks often cover all 50 states, so you are not waiting on the slowest board.
Cons of white-labeling
- Less control of the patient relationship: In important ways, the patient is also the network’s patient.
- Less control of data in practice: Even if a contract says you “own” the data, access and portability can be limited when you try to leave.
- Constraints on protocols and brand experience: You often operate within the network’s approved protocols and formulary.
- Thinner unit economics: Per-visit or per-script pricing can become a permanent margin leak at scale.
- Dependency risk: Pricing changes, protocol changes, or network ownership changes can hit your business directly.
White-labeling can be a smart way to validate demand and launch quickly. The key is not confusing “quick” with “permanent.”
Option 2: The PC/MSO model
In a PC/MSO model (also called “friendly PC” or MSO-PC), you create two coordinated entities:
- A professional corporation (PC) owned by a licensed physician that employs clinicians and practices medicine
- A management services organization (MSO) that you own, and raise capital into, that provides non-clinical support like technology, marketing, billing, scheduling, HR, and administration
The MSO is typically paid a fair-market-value management fee under a carefully drafted management services agreement (MSA). Additional agreements are often used to create continuity and protect the relationship while respecting CPOM and fee-splitting rules.
Pros of the PC/MSO model
- Control: You own the brand and patient experience, and you can build differentiated workflows.
- Data ownership in practice: Patient and clinical data lives in your systems, which supports analytics and enterprise value.
- Better long-term economics: At scale, owning the clinical operation often beats paying per-visit markups forever.
- Stronger defensibility and valuation: Investors and acquirers often value owned infrastructure more than rented infrastructure.
Cons of the PC/MSO model
- Higher cost and complexity: You are forming entities, building infrastructure, and drafting multiple agreements.
- Slower to launch: Multi-state entity formation and licensure can take months.
- Ongoing compliance burden: CPOM rules vary by state and require continuing attention.
- You need the right physician partner: The PC owner must be someone you trust, and succession and control mechanics must be drafted correctly.
PC/MSO is usually the long-term “own the engine” solution. It is not always the best way to launch from day one.
The contract trap
Here is the single most important practical point if you start with a white-label network:
Make sure your contract preserves a clean path to transition into your own PC/MSO later.
Choosing to white-label first is often the right call. Getting stuck there because your agreement makes leaving impossible is the mistake that shows up at the worst moment, usually during financing or a sale process.
Before you sign, have counsel scrutinize these terms:
- Data ownership and portability: Can you export records in a usable format, on a defined timeline, when you exit?
- Patient relationship and non-solicitation: Can the network treat “your” patients as theirs if you leave?
- Exclusivity and minimums: Are you blocked from building your own PC in parallel, or locked into volume commitments?
- Term, termination, and transition support: How long is the commitment and does the network have to help with an orderly migration?
- Non-compete and IP: Do protocols, intake flows, or assets you helped shape stay trapped behind the vendor?
Negotiated correctly, a white-label agreement becomes a launchpad. Negotiated poorly, it becomes a cage.
The hybrid model: best of both
Many telehealth companies do not flip a switch from white-label to PC/MSO. Instead, they adopt a hybrid model:
- Build PC/MSO in core, high-volume states where control and economics justify it
- Keep white-label coverage in states where you do not yet have your own footprint
This approach can help you:
- Capture margin and control where it matters most
- Expand ownership state-by-state instead of betting everything on one cutover
- Maintain national coverage so growth and marketing never need to pause
Done well, hybrid is a phased migration strategy: white-label is your on-ramp and your long-tail coverage, while your PC/MSO gradually absorbs the states that drive the business. The key is simple: your white-label contract must allow coexistence and eventual wind-down.
A simple decision framework
Use this framework to choose your structure based on stage and goals:
Pre-revenue or validating demand
Start with a well-negotiated white-label agreement. Prove demand before building infrastructure.
Growing, with demand concentrated in a few states
Move to a hybrid model. Build PC/MSO in top markets while keeping white-label everywhere else.
At scale, differentiated, or preparing for a raise or exit
Transition to full PC/MSO so you own the patients, the data, and the economics that drive enterprise value.
Category risk matters too
Some categories carry regulatory complexity that may push you toward owning and controlling your clinical operation sooner rather than later. If your model is more differentiated or more heavily regulated, control becomes more valuable.
Frequently Asked Questions
Is white-labeling legal for a telehealth startup?
Yes. White-labeling through a licensed medical network is a common way to launch because the network holds the licensure and employs clinicians. The bigger risk is usually the contract terms and whether you preserved a path to ownership.
What is a PC/MSO, friendly PC, model?
It is a two-entity structure: a physician-owned PC practices medicine and employs clinicians, while your MSO provides non-clinical services for a fair-market-value fee under a management services agreement.
When should I switch from white-label to PC/MSO?
Often when your volume makes per-visit pricing more expensive than running your own operation, when you need protocol or brand control that the network will not allow, or when you are preparing for a financing or sale where owned infrastructure increases valuation.
Can I use both models at the same time?
Yes. That is the hybrid model. You run PC/MSO in core states and white-label in other states as you expand coverage over time, assuming your white-label agreement allows it.
What are the biggest contract terms to negotiate in a white-label agreement?
Data ownership and portability, patient relationship protections, exclusivity and minimums, termination and transition support, and any non-compete or IP restrictions that could block your future plan.
How does this affect enterprise value?
In general, companies that own their patient relationship, data, and clinical infrastructure often present stronger enterprise value than companies that rent the clinical backend indefinitely.
Talk to LumaLex Law about telehealth structuring
If you are thinking through how to structure your telehealth company, LumaLex Law helps founders build and transition between white-label, PC/MSO, and hybrid models, and negotiate the contracts that keep options open.
Book a telehealth structuring consultation to pressure-test your model, protect your future exit path, and build a structure that can scale. Contact LumaLex Law today to get started.
Disclaimer: This article is provided for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Telehealth and healthcare rules vary by state and change frequently. Consult qualified counsel about your specific facts.
